The global Carcinoid tumor syndrome management market garnered a market value of US$ 1774.38 Million in 2023 and is expected to accumulate a market value of US$ 4993 Million by registering a CAGR of 10.9% in the forecast period 2023 to 2033. Growth of the Carcinoid tumor syndrome management market can be attributed to increasing prevalence of the ailment along with availability of different treatments. The market for Carcinoid tumor syndrome management registered a CAGR of 7.3% in the historical period 2016 to 2021
Carcinoid tumor syndrome is a rare condition caused by a type of tumor called a carcinoid tumor. Carcinoid tumors are usually found in the gastrointestinal tract, but can also occur in other parts of the body such as the lungs and ovaries. These tumors produce hormones and chemicals, including serotonin, that can cause a variety of symptoms in affected individuals. Symptoms can include flushing of the skin, diarrhea, wheezing, abdominal pain, and heart palpitations.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 1774.38 Million |
| Anticipated Forecast Value (2033) | US$ 4993 Million |
| Projected Growth Rate (2023 to 2033) | 10.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Carcinoid tumor syndrome management reflected a value of 7.3% during the historical period, 2018 to 2022.
Factors driving the growth of the CTS management market include increasing awareness of the disease, rising incidence of neuroendocrine tumors, and the development of new treatment options. However, the high cost of treatment and limited availability of therapies in some regions may hinder market growth. The management of CTS typically involves treating the symptoms and controlling tumor growth.
Thus, the market for Carcinoid tumor syndrome management is expected to register a CAGR of 10.9% in the forecast period 2023 to 2033.
Increasing investment in research and development activities bosting market growth of Carcinoid tumor syndrome management market
The incidence of carcinoid tumor syndrome is increasing, which is leading to the growth of the market. According to the National Organization for Rare Disorders, carcinoid tumors affect around 5 in every 100,000 people worldwide. Advancements in diagnostic techniques such as CT scans, MRI, and PET scans have improved the detection of carcinoid tumors, enabling early diagnosis and treatment. In addition, there has been a significant development in treatment options such as surgery, radiation therapy, and chemotherapy, leading to better management of the disease.
Increased awareness among patients and healthcare providers about the disease is driving the demand for better management options. This is leading to the development of new and innovative therapies for the treatment of carcinoid tumor syndrome. Governments are taking initiatives to promote research and development in the field of carcinoid tumor syndrome. The Orphan Drug Act, passed in the United States in 1983, offers financial incentives to companies that develop drugs for rare diseases like carcinoid tumor syndrome.
The market is also driven by increasing investment in research and development activities for the development of new drugs and therapies for the treatment of carcinoid tumor syndrome. Pharmaceutical companies are investing heavily in the development of novel therapies that target specific signaling pathways involved in the progression of the disease.
Overall, the increasing prevalence of carcinoid tumor syndrome, advancements in diagnosis and treatment, growing awareness, government initiatives, and increasing investment in research and development activities are the major drivers of the Carcinoid Tumor Syndrome Management market.
Availability of different treatments shaping landscape for Carcinoid tumor syndrome management market
Surgery: Surgical removal of the tumor is the primary treatment for carcinoid tumors. Surgery is typically recommended for patients with localized tumors that have not spread to other organs.
Medications: Medications can be used to control the symptoms of carcinoid tumor syndrome. These include
Radiation Therapy: Radiation therapy may be used to shrink the size of the tumor, reduce symptoms, and prevent the tumor from spreading to other parts of the body.
Chemotherapy: Chemotherapy may be recommended for more advanced or aggressive tumors that have spread to other organs.
Supportive Care: Supportive care includes managing symptoms such as diarrhea, flushing, and heart palpitations. Patients with carcinoid tumor syndrome should also receive regular check-ups to monitor the tumor's growth and manage symptoms as they arise.
Overall, the management of carcinoid tumor syndrome depends on the size and location of the tumor, as well as the severity of the symptoms. A multidisciplinary team, including medical oncologists, surgeons, and endocrinologists, provide the best care and management for patients with carcinoid tumor syndrome.
Principal Consultant
Expensive nature of treatment along with resistance building towards the ailment affecting market growth
CTS is a rare disease, and many healthcare professionals may not be familiar with its symptoms and proper diagnosis. As a result, patients may be misdiagnosed, leading to delays in treatment and potentially worsening outcomes. The management of CTS can be costly, as it often involves the use of specialized medications such as somatostatin analogs and targeted therapies. Patients may struggle to afford these treatments, and insurers may not cover all the costs.
Some of the specialized medications used in CTS management are not widely available in all regions. This can lead to delays in treatment, as patients may need to travel to receive care. Some of the medications used in CTS management can cause adverse side effects, which may limit their effectiveness or lead to the need for additional treatments.
Some CTS tumors may become resistant to certain treatments over time, making it more difficult to manage the disease and potentially limiting treatment options.
Availability of treatment options creating lucrative opportunities for carcinoid tumor management market
The North American Carcinoid Tumor Syndrome (CTS) management market is a significant market in the healthcare industry. The region consists of the United States and Canada, where the prevalence of neuroendocrine tumors, including carcinoid tumors, is increasing. According to a report by the American Cancer Society, approximately 12,000 cases of carcinoid tumors are diagnosed in the United States each year.
The CTS management market in North America is primarily driven by factors such as the increasing incidence of neuroendocrine tumors, rising awareness of the disease, and the availability of advanced treatment options. North America has a well-established healthcare infrastructure and regulatory framework, which has enabled the development and commercialization of new treatments for CTS management.
The market comprises various treatment options, including somatostatin analogs, chemotherapy, and targeted therapies. The somatostatin analogs segment dominates the market due to their efficacy in controlling the symptoms of CTS. Other emerging treatment options, such as peptide receptor radionuclide therapy (PRRT), are also gaining traction in the North American market. Thus, North America is expected to possess 44% market share for carcinoid tumor syndrome management market in 2023.
Well-established healthcare infrastructure increasing dependency on hospitals for treatment of carcinoid tumor management market
The Europe Carcinoid Tumor Syndrome (CTS) management market remains an important market in the healthcare industry. The region consists of countries such as Germany, France, Italy, Spain, and the United Kingdom, where the prevalence of neuroendocrine tumors, including carcinoid tumors, continues to increase.
The CTS management market in Europe is primarily driven by factors such as the increasing incidence of neuroendocrine tumors, rising awareness of the disease, and the availability of advanced treatment options. Europe also has a well-established healthcare infrastructure and regulatory framework, which has facilitated the development and commercialization of new treatments for CTS management.
The market comprises various treatment options, including somatostatin analogs, chemotherapy, and targeted therapies. The somatostatin analogs segment continues to dominate the market due to their efficacy in controlling the symptoms of CTS. Other emerging treatment options, such as peptide receptor radionuclide therapy (PRRT) and immunotherapy, are also gaining traction in the European market.
In addition, the European Union has implemented regulations such as the Orphan Medicinal Products Regulation and the Priority Medicines (PRIME) scheme to incentivize the development of treatments for rare diseases such as CTS. These regulations may help to drive innovation in CTS management and improve access to treatments for patients in Europe. Overall, the Europe CTS management market is expected to continue to grow in the coming years as the prevalence of the disease increases and new treatment options become available. Thus, Europe is expected to possess 37% market share for carcinoid tumor management market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Sustained effects of orally consumed medications making them popular
The oral route of administration is one of the most commonly used methods for the management of CTS symptoms. This is because many of the medications used to control the symptoms of CTS, such as somatostatin analogs like octreotide and lanreotide, are available in oral formulations.
Oral medications are generally easy to take and are convenient for patients to self-administer. They also provide a sustained effect and can be used to maintain symptom control over an extended period of time. Thus, oral route of administration is expected to possess 55% market share for carcinoid tumor management market in 2023.
Key players in the Carcinoid tumor syndrome management are Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Ipsen Biopharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Amgen Inc., Entrinsic Health Solutions, Inc., Endo Pharmaceuticals Inc., Sirtex SIR-Spheres Pty Ltd, BTG International Ltd
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 1774.38 Million |
| Market Value in 2033 | US$ 4993 Million |
| Growth Rate | CAGR of 10.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market advanced at a CAGR of 7.3% from 2018 to 2022.
Increasing investment in research and development activities and Increased awareness among patients and healthcare providers about the disease creates demand.
Increasing incidence of neuroendocrine tumors, rising awareness of the disease, and the availability of advanced treatment options drive the market.
Key players in Carcinoid tumor syndrome management are Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., and Ipsen Biopharmaceuticals, Inc.
Targeted Therapies and Well-established healthcare infrastructure lead to market demand in Europe.
1. Executive Summary | Carcinoid Tumor Syndrome Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Organ Affected 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Organ Affected, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Organ Affected, 2023 to 2033 5.3.1. Small Intestine 5.3.2. Lungs 5.3.3. Rectum 5.3.4. Appendix 5.3.5. Stomach 5.3.6. Liver 5.3.7. Others 5.4. Y-o-Y Growth Trend Analysis By Organ Affected, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Organ Affected, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033 6.3.1. Chemotherapy 6.3.2. Biological Therapy 6.3.3. Radiotherapy 6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug , 2023 to 2033 7.3.1. Octreotide 7.3.2. Telotristat Etiprate 7.3.3. Lanreotide 7.4. Y-o-Y Growth Trend Analysis By Drug , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Drug , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 8.3.1. Oral 8.3.2. Injectable 8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 9.3.1. Retail Pharmacies 9.3.2. Hospital Pharmacies 9.3.3. Online Pharmacies 9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. MEA 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. USA 11.2.1.2. Canada 11.2.2. By Organ Affected 11.2.3. By Therapy Type 11.2.4. By Drug 11.2.5. By Route of Administration 11.2.6. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Organ Affected 11.3.3. By Therapy Type 11.3.4. By Drug 11.3.5. By Route of Administration 11.3.6. By Distribution Channel 11.4. Key Takeaways 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Organ Affected 12.2.3. By Therapy Type 12.2.4. By Drug 12.2.5. By Route of Administration 12.2.6. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Organ Affected 12.3.3. By Therapy Type 12.3.4. By Drug 12.3.5. By Route of Administration 12.3.6. By Distribution Channel 12.4. Key Takeaways 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United kingdom 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Europe 13.2.2. By Organ Affected 13.2.3. By Therapy Type 13.2.4. By Drug 13.2.5. By Route of Administration 13.2.6. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Organ Affected 13.3.3. By Therapy Type 13.3.4. By Drug 13.3.5. By Route of Administration 13.3.6. By Distribution Channel 13.4. Key Takeaways 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Rest of South Asia 14.2.2. By Organ Affected 14.2.3. By Therapy Type 14.2.4. By Drug 14.2.5. By Route of Administration 14.2.6. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Organ Affected 14.3.3. By Therapy Type 14.3.4. By Drug 14.3.5. By Route of Administration 14.3.6. By Distribution Channel 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Organ Affected 15.2.3. By Therapy Type 15.2.4. By Drug 15.2.5. By Route of Administration 15.2.6. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Organ Affected 15.3.3. By Therapy Type 15.3.4. By Drug 15.3.5. By Route of Administration 15.3.6. By Distribution Channel 15.4. Key Takeaways 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. Australia 16.2.1.2. New Zealand 16.2.2. By Organ Affected 16.2.3. By Therapy Type 16.2.4. By Drug 16.2.5. By Route of Administration 16.2.6. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Organ Affected 16.3.3. By Therapy Type 16.3.4. By Drug 16.3.5. By Route of Administration 16.3.6. By Distribution Channel 16.4. Key Takeaways 17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. GCC Countries 17.2.1.2. South Africa 17.2.1.3. Israel 17.2.1.4. Rest of MEA 17.2.2. By Organ Affected 17.2.3. By Therapy Type 17.2.4. By Drug 17.2.5. By Route of Administration 17.2.6. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Organ Affected 17.3.3. By Therapy Type 17.3.4. By Drug 17.3.5. By Route of Administration 17.3.6. By Distribution Channel 17.4. Key Takeaways 18. Key Countries Market Analysis 18.1. USA 18.1.1. Pricing Analysis 18.1.2. Market Share Analysis, 2022 18.1.2.1. By Organ Affected 18.1.2.2. By Therapy Type 18.1.2.3. By Drug 18.1.2.4. By Route of Administration 18.1.2.5. By Distribution Channel 18.2. Canada 18.2.1. Pricing Analysis 18.2.2. Market Share Analysis, 2022 18.2.2.1. By Organ Affected 18.2.2.2. By Therapy Type 18.2.2.3. By Drug 18.2.2.4. By Route of Administration 18.2.2.5. By Distribution Channel 18.3. Brazil 18.3.1. Pricing Analysis 18.3.2. Market Share Analysis, 2022 18.3.2.1. By Organ Affected 18.3.2.2. By Therapy Type 18.3.2.3. By Drug 18.3.2.4. By Route of Administration 18.3.2.5. By Distribution Channel 18.4. Mexico 18.4.1. Pricing Analysis 18.4.2. Market Share Analysis, 2022 18.4.2.1. By Organ Affected 18.4.2.2. By Therapy Type 18.4.2.3. By Drug 18.4.2.4. By Route of Administration 18.4.2.5. By Distribution Channel 18.5. Germany 18.5.1. Pricing Analysis 18.5.2. Market Share Analysis, 2022 18.5.2.1. By Organ Affected 18.5.2.2. By Therapy Type 18.5.2.3. By Drug 18.5.2.4. By Route of Administration 18.5.2.5. By Distribution Channel 18.6. United kingdom 18.6.1. Pricing Analysis 18.6.2. Market Share Analysis, 2022 18.6.2.1. By Organ Affected 18.6.2.2. By Therapy Type 18.6.2.3. By Drug 18.6.2.4. By Route of Administration 18.6.2.5. By Distribution Channel 18.7. France 18.7.1. Pricing Analysis 18.7.2. Market Share Analysis, 2022 18.7.2.1. By Organ Affected 18.7.2.2. By Therapy Type 18.7.2.3. By Drug 18.7.2.4. By Route of Administration 18.7.2.5. By Distribution Channel 18.8. Spain 18.8.1. Pricing Analysis 18.8.2. Market Share Analysis, 2022 18.8.2.1. By Organ Affected 18.8.2.2. By Therapy Type 18.8.2.3. By Drug 18.8.2.4. By Route of Administration 18.8.2.5. By Distribution Channel 18.9. Italy 18.9.1. Pricing Analysis 18.9.2. Market Share Analysis, 2022 18.9.2.1. By Organ Affected 18.9.2.2. By Therapy Type 18.9.2.3. By Drug 18.9.2.4. By Route of Administration 18.9.2.5. By Distribution Channel 18.10. India 18.10.1. Pricing Analysis 18.10.2. Market Share Analysis, 2022 18.10.2.1. By Organ Affected 18.10.2.2. By Therapy Type 18.10.2.3. By Drug 18.10.2.4. By Route of Administration 18.10.2.5. By Distribution Channel 18.11. Malaysia 18.11.1. Pricing Analysis 18.11.2. Market Share Analysis, 2022 18.11.2.1. By Organ Affected 18.11.2.2. By Therapy Type 18.11.2.3. By Drug 18.11.2.4. By Route of Administration 18.11.2.5. By Distribution Channel 18.12. Singapore 18.12.1. Pricing Analysis 18.12.2. Market Share Analysis, 2022 18.12.2.1. By Organ Affected 18.12.2.2. By Therapy Type 18.12.2.3. By Drug 18.12.2.4. By Route of Administration 18.12.2.5. By Distribution Channel 18.13. Thailand 18.13.1. Pricing Analysis 18.13.2. Market Share Analysis, 2022 18.13.2.1. By Organ Affected 18.13.2.2. By Therapy Type 18.13.2.3. By Drug 18.13.2.4. By Route of Administration 18.13.2.5. By Distribution Channel 18.14. China 18.14.1. Pricing Analysis 18.14.2. Market Share Analysis, 2022 18.14.2.1. By Organ Affected 18.14.2.2. By Therapy Type 18.14.2.3. By Drug 18.14.2.4. By Route of Administration 18.14.2.5. By Distribution Channel 18.15. Japan 18.15.1. Pricing Analysis 18.15.2. Market Share Analysis, 2022 18.15.2.1. By Organ Affected 18.15.2.2. By Therapy Type 18.15.2.3. By Drug 18.15.2.4. By Route of Administration 18.15.2.5. By Distribution Channel 18.16. South Korea 18.16.1. Pricing Analysis 18.16.2. Market Share Analysis, 2022 18.16.2.1. By Organ Affected 18.16.2.2. By Therapy Type 18.16.2.3. By Drug 18.16.2.4. By Route of Administration 18.16.2.5. By Distribution Channel 18.17. Australia 18.17.1. Pricing Analysis 18.17.2. Market Share Analysis, 2022 18.17.2.1. By Organ Affected 18.17.2.2. By Therapy Type 18.17.2.3. By Drug 18.17.2.4. By Route of Administration 18.17.2.5. By Distribution Channel 18.18. New Zealand 18.18.1. Pricing Analysis 18.18.2. Market Share Analysis, 2022 18.18.2.1. By Organ Affected 18.18.2.2. By Therapy Type 18.18.2.3. By Drug 18.18.2.4. By Route of Administration 18.18.2.5. By Distribution Channel 18.19. GCC Countries 18.19.1. Pricing Analysis 18.19.2. Market Share Analysis, 2022 18.19.2.1. By Organ Affected 18.19.2.2. By Therapy Type 18.19.2.3. By Drug 18.19.2.4. By Route of Administration 18.19.2.5. By Distribution Channel 18.20. South Africa 18.20.1. Pricing Analysis 18.20.2. Market Share Analysis, 2022 18.20.2.1. By Organ Affected 18.20.2.2. By Therapy Type 18.20.2.3. By Drug 18.20.2.4. By Route of Administration 18.20.2.5. By Distribution Channel 18.21. Israel 18.21.1. Pricing Analysis 18.21.2. Market Share Analysis, 2022 18.21.2.1. By Organ Affected 18.21.2.2. By Therapy Type 18.21.2.3. By Drug 18.21.2.4. By Route of Administration 18.21.2.5. By Distribution Channel 19. Market Structure Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Market Share Analysis of Top Players 19.3.1. By Regional 19.3.2. By Organ Affected 19.3.3. By Therapy Type 19.3.4. By Drug 19.3.5. By Route of Administration 19.3.6. By Distribution Channel 20. Competition Analysis 20.1. Competition Deep Dive 20.1.1. Novartis AG 20.1.1.1. Overview 20.1.1.2. Product Portfolio 20.1.1.3. Profitability by Market Segments 20.1.1.4. Sales Footprint 20.1.1.5. Strategy Overview 20.1.1.5.1. Marketing Strategy 20.1.2. Teva Pharmaceutical Industries Ltd. 20.1.2.1. Overview 20.1.2.2. Product Portfolio 20.1.2.3. Profitability by Market Segments 20.1.2.4. Sales Footprint 20.1.2.5. Strategy Overview 20.1.2.5.1. Marketing Strategy 20.1.3. Mylan N.V. 20.1.3.1. Overview 20.1.3.2. Product Portfolio 20.1.3.3. Profitability by Market Segments 20.1.3.4. Sales Footprint 20.1.3.5. Strategy Overview 20.1.3.5.1. Marketing Strategy 20.1.4. Ipsen Biopharmaceuticals, Inc 20.1.4.1. Overview 20.1.4.2. Product Portfolio 20.1.4.3. Profitability by Market Segments 20.1.4.4. Sales Footprint 20.1.4.5. Strategy Overview 20.1.4.5.1. Marketing Strategy 20.1.5. Sun Pharmaceutical Industries Ltd 20.1.5.1. Overview 20.1.5.2. Product Portfolio 20.1.5.3. Profitability by Market Segments 20.1.5.4. Sales Footprint 20.1.5.5. Strategy Overview 20.1.5.5.1. Marketing Strategy 20.1.6. Amgen Inc. 20.1.6.1. Overview 20.1.6.2. Product Portfolio 20.1.6.3. Profitability by Market Segments 20.1.6.4. Sales Footprint 20.1.6.5. Strategy Overview 20.1.6.5.1. Marketing Strategy 20.1.7. Entrinsic Health Solutions, Inc. 20.1.7.1. Overview 20.1.7.2. Product Portfolio 20.1.7.3. Profitability by Market Segments 20.1.7.4. Sales Footprint 20.1.7.5. Strategy Overview 20.1.7.5.1. Marketing Strategy 20.1.8. Endo Pharmaceuticals Inc. 20.1.8.1. Overview 20.1.8.2. Product Portfolio 20.1.8.3. Profitability by Market Segments 20.1.8.4. Sales Footprint 20.1.8.5. Strategy Overview 20.1.8.5.1. Marketing Strategy 20.1.9. Sirtex SIR-Spheres Pty Ltd 20.1.9.1. Overview 20.1.9.2. Product Portfolio 20.1.9.3. Profitability by Market Segments 20.1.9.4. Sales Footprint 20.1.9.5. Strategy Overview 20.1.9.5.1. Marketing Strategy 20.1.10. BTG International Ltd 20.1.10.1. Overview 20.1.10.2. Product Portfolio 20.1.10.3. Profitability by Market Segments 20.1.10.4. Sales Footprint 20.1.10.5. Strategy Overview 20.1.10.5.1. Marketing Strategy 21. Assumptions & Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Carcinoid Tumor Syndrome Management Market
